# 家族經營的義大利製藥集團Chiesi透過數十億美元的收購擴大其在美國的布局。

*biotech, business · news · 2026-04-29 · MarketScreener*

## Key points

- Chiesi以19億美元收購KalVista，創下其有史以來最大交易。
- Chiesi將利用現金儲備及新債務來資助此次收購。
- KalVista的遺傳性血管性水腫治療是Chiesi預期在美國成長的核心。
- Chiesi預計其營收將從2024年的36億歐元增長至2030年的60億歐元。

Family-owned Italian pharmaceutical group Chiesi is expanding its U.S. footprint through a multi-billion dollar acquisition. The company offered KalVista shareholders 27 dollars per share on Wednesday, representing a total cash consideration of 1.9 billion dollars. Following the announcement, KalVista shares surged as much as 39.1 percent on Wall Street, hitting a five-year high of 26.76 dollars. With the largest acquisition in its corporate history, Chiesi aims to bolster its rare disease portfolio and increase its market share in the United States. According to the companies, the boards of both firms have unanimously approved the transaction. An insider stated that Chiesi is financing the deal through a combination of existing cash reserves and new debt. The group currently holds 729 million euros in cash. The Italian pharmaceutical firm generated 3.6 billion euros in revenue in 2024. This figure is projected to rise to six billion euros by 2030. Chiesi expects a significant growth boost primarily from KalVista's treatment for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and painful swelling. (Reporting by Giancarlo Navach; writing by Hakan Ersen, edited by Ralf Banser. For inquiries, please contact our editorial team at berlin.newsroom@thomsonreuters.com (for politics and economics) or frankfurt.newsroom@thomsonreuters.com (for corporate and markets).)

**Companies:** Chiesi, KalVista
**Countries:** Italy, United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/italian-pharma-group-chiesi-to-acquire-u-s-rival-kalvista-ce7f58dada8af021)

---

Canonical: https://newsio.io/zh-TW/n/edadfcfb-8547-4c7b-ace7-5746dc89c732/chiesikalvista2719
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works